GEHC News & Events

GE HealthCare announced its industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of EUR 50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI.

At ACC.26, GE HealthCare will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout the patient journey. GE HealthCare will highlight continued advancement in photon-counting CT with the newly U.S. FDA 510(k) cleared Photonova Spectra, an AI-enabled imaging system, powered by proprietary Deep Silicon detectors. Photon-counting CT directly measures individual X-ray photons and their energy, enabling ultra-high-definition imaging, improved tissue characterization and enhanced material differentiation. For cardiology, this advancement is designed to support more detailed visualization of coronary anatomy, plaque characterization and dose-conscious cardiac imaging - with the aim of helping clinicians gain greater diagnostic confidence. For the first time at a U.S. cardiology event, GE HealthCare will showcase ReadyFix fleet management solutionii enabled to work with MAC VU360 resting electrocardiodiagrams workstations. Recently launched in the U.S., ReadyFix works with MAC VU360 to help optimize cardiac care delivery and device uptime through access to real-timeiii data and remote software deployment configuration management and diagnostics. ReadyFix can help health systems proactively maintain and optimize MAC VU360 performance, remotely from a centralized dashboard, to reduce device-related disruptions - supporting care teams in providing consistent, quality care for patients. At ACC.26, GE HealthCare will highlight how it continues to advance its offerings for the cardiac catheterization lab through intelligent imaging, workflow-focused interventional solutions, and collaborations designed to broaden access to complementary technologies. This includes its recent agreement with Gentuity in the U.S., which will seamlessly connect GE HealthCare customers with Gentuity HF-OCT and Vis-Rx PRIME Micro-Imaging Catheter. Together, these technologies are designed to support percutaneous coronary intervention planning, and enhanced intraprocedural visualization in complex coronary procedures. This news builds on recent momentum across GE HealthCare's interventional portfolio, including the recent U.S. FDA 510(k) clearance and CE Mark for Allia Moveo, the latest Allia IGS platform designed to assist clinicians across a wide range of interventional procedures.

GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration for Photonova Spectra, a photon-counting computed tomography solution powered by the company's novel Deep Silicon detector technology and offered as a flexible platform with multiple configurations to meet diverse clinical needs. With wide coverage and the combination of ultra-high definition spatial and spectral imaging, Photonova Spectra helps enable fast acquisition speeds and the precise visualization of subtle tissue variations, small lesions and vascular structures.